Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in the Netherlands

Pediatric Infectious Disease Journal

Volumn 27, Issue 3, 2008, Pages 218-223

  De Greeff, Sabine C ^a,b   Mooi, Frits R ^b   Schellekens, Joop F P ^c   De Melker, Hester E ^a  

^a Centre for Infectious Disease Control   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c Laboratory for Infectious Diseases   (Netherlands)

Author keywords

Epidemiology; Pertussis; The Netherlands; Vaccination

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; INFANRIX IPV HIB; PEDIACEL; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; ACELLULAR VACCINE;

ARTICLE; CHILD; DISEASE TRANSMISSION; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REVACCINATION; VACCINATION; ADOLESCENT; ADULT; AGE; AGED; COMPARATIVE STUDY; FEMALE; HOSPITALIZATION; IMMUNIZATION; IMMUNOLOGY; INCIDENCE; INFANT; INFECTION CONTROL; MALE; MIDDLE AGED; NEWBORN;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISEASE NOTIFICATION; FEMALE; HOSPITALIZATION; HUMANS; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NETHERLANDS; PERTUSSIS VACCINE; VACCINES, ACELLULAR; WHOOPING COUGH;

EID: 44949217712     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318161a2b9     Document Type: Article

References (38)

1. Preziosi MP, Halloran ME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis. 2003;379: 772-779.
2. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6:348-357.
3. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ. Polymorphism in the Bordetella pertussis virulence factors P. 69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun. 1998;66:670-675.
4. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europe. Pediatr Infect Dis J. 2005;24:761-765.
5. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-1237.
6. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J. 2003;22:22-27.
7. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA. 2003;290:2968-2975.
8. Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J. 2003;22:628-634.
9. Schellekens J, von Konig CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr Infect Dis J. 2005;24:S19-S24.0
10. Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis. 2007;7:614-624.1
11. Forsyth K, Tan T, von Konig CH, Caro JJ, Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J. 2005;24:S69-S74.2
12. Torvaldsen S, McIntyre PB. Effect of the preschool pertussis booster on national notifications of disease in Australia. Pediatr Infect Dis J. 2003;22:956-959.3
13. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR. 2002;49:1-90.4
14. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol. 2000;38:800-806.5
15. van der Zee A, Agterberg C, Peeters M, Mooi F, Schellekens J. A clinical validation of Bordetella pertussis and Bordetella parapertussis polymerase chain reaction: comparison with culture and serology using samples from patients with suspected whooping cough from a highly immunized population. J Infect Dis. 1996;174:89-96.6
16. de Greeff SC, Schellekens JFP, Mooi FR, de Melker HE. Pertussis in the Netherlands 2001-2002. Available at: http://www.rivm.nl/bibliotheek/rapporten/ 128507010.html. Accessed June 26, 2007.7
17. Farrington CP. Estimation of vaccine effectiveness using the screening method. Int J Epidemiol. 1993;22:742-746.8
18. Abbink F, Oomen PJ, Zwakhals SLN, de Melker HE, Ambler-Huiskes A. Immunization coverage in the Netherlands as at 1 January 2005. Available at: http://www.rivm.nl/bibliotheek/rapporten/210021005.html. Accessed June 26, 2007.9
19. Hightower AW, Orenstein WA, Martin SM. Recommendations for the use of Taylor series confidence intervals for estimates of vaccine efficacy. Bull World Health Organ. 1988;66:99-105.0
20. K. Rothman. Episheet -worksheet on the internet- Version November 2005. Available at: http://members.aol.com/krothman/modepi.htm. Accessed June 20, 2007.1
21. de Greeff SC, Schellekens JF, Mooi FR, de Melker HE. -Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003.- Ned Tijdschr Geneeskd. 2005;149:937-943.2
22. Hallander HO, Gustafsson L, Ljungman M, Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 3 1/2-6 1/2 years after the third vaccine dose. Vaccine. 2005;23: 5359-5364.3
23. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006;118:978-984.4
24. Somerville RL, Grant CC, Scragg RK, Thomas MG. Hospitalisations due to pertussis in New Zealand in the pre-immunisation and mass immunisation eras. J Paediatr Child Health. 2007;43:147-153.5
25. Hviid A, Stellfeld M, Wohlfahrt J, Andersen PH, Melbye M. The impact of pre-school booster vaccination of 4-6-year-old children on pertussis in 0-1-year-old children. Vaccine. 2006;24:1401-1407.6
26. Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis. 2002;185: 1448-1453.7
27. Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J. 1998;17:412-418.8
28. Grimprel E, Baron S, Levy-Bruhl D, et al. Infiuence of vaccination coverage on pertussis transmission in France. Lancet. 1999;354:1699-1700.9
29. Elliott E, McIntyre P, Ridley G, et al. National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J. 2004;23:246-252.0
30. Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J. 2004;23:985-989.1
31. de Melker HE, Versteegh FG, Schellekens JF, Teunis PF, Kretzschmar M. The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect. 2006; 53:106-113.2
32. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006;367:1926-1936.3
33. Cherry JD. Immunity to pertussis. Clin Infect Dis. 2007;44:1278-1279.4
34. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis. 2001;7:526-528.5
35. King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi FR. Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology. 2001;147:2885-2895.6
36. Gzyl A, Augustynowicz E, Gniadek G, Rabczenko D, Dulny G, Slusarczyk J. Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine. 2004;22:2122-2128.7
37. Van Rie A, Hethcote HW. Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine. 2004;22:3154-3165.8
38. Edelman K, He Q, Makinen J, Sahlberg A, et al. Immunity to pertussis 5 years after booster immunization during adolescence. Clin Infect Dis. 2007;44:1271-1277.